Zoetis Inc.
NYSE:ZTSDrug Manufacturers - General
+$1.17 today
- Market cap
- $34.76B
- Beta
- 0.74
- P/E (TTM)
- 12.5
- EPS (TTM)
- $6.26
- Dividend yield
- 2.63%
Volume 4.66M
Average 6.20M
ZTS Total Non-current Liabilities
All obligations due after more than one year.
Zoetis Inc.NYSE: ZTS
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities rises 60.8% from a year ago
Total non-current liabilities stood at $9.87B at the end of Q2 FY2026, up 60.8% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.
Context
- Total non-current liabilities amounted to 65.5% of total assets at the end of Q2 FY2026, up 23.1 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +60.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.9B USD
- Year-over-year change
- +63.5%
- 4-year CAGR
- +7.0%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.9B | +63.5% |
| FY2024 | 2024-12-31 | 6.06B | -18.2% |
| FY2023 | 2023-12-31 | 7.41B | +0.7% |
| FY2022 | 2022-12-31 | 7.36B | -2.7% |
| FY2021 | 2021-12-31 | 7.56B | — |
Total Non-current Liabilities vs competitors
How ZTS compares with its peers on the latest reported figures
- ZTS's Jun 2026 total non-current liabilities of $9.87B is the 2nd highest of the 6 companies compared; the peer median is $1.07B.
- Its year-over-year change of +60.8% is the highest of 6, against a peer median of -4.1%.
- Total non-current liabilities amounts to 65.5% of total assets for ZTS, versus a peer median of 36.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $60.09B | +41.6% | +12.9% | 46.3% | |
| Jun 2026 | $9.87B | +60.8% | +10.4% | 65.5% | |
| Sep 2026 | $4.93B | -7.9% | -7.1% | 36.9% | |
| Aug 2026 | $1.07B | -4.1% | -4.9% | 32.3% | |
| Mar 2026 | $801.42M | +2.1% | +17.8% | 55.5% | |
| Sep 2026 | $158.7M | -72.3% | -12.9% | 4.3% | |
| Peer median (excluding ZTS) | $1.07B | -4.1% | -4.9% | 36.9% | |
Competitors are the stored peer set for ZTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.48B | 3.58B | 2.04B | 1.99B | 2.31B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.13B | 1.22B | 1.3B | 1.32B | 1.59B |
| Inventory | 1.92B | 2.35B | 2.56B | 2.31B | 2.43B |
| Other Current Assets | 392M | 369M | 436M | 379M | 436M |
| Total Current Assets | 6.93B | 7.51B | 6.34B | 5.99B | 6.77B |
| Property, Plant & Equipment (Net) | 2.6B | 2.97B | 3.43B | 3.61B | 3.97B |
| Goodwill | 2.68B | 2.75B | 2.76B | 2.72B | 2.77B |
| Intangible Assets | 1.47B | 1.38B | 1.34B | 1.13B | 998M |
| Long-term Investments | 0 | 0 | 0 | 30M | 0 |
| Tax Assets | 100M | 173M | 206M | 540M | 637M |
| Other Non-current Assets | 111M | 147M | 206M | 220M | 328M |
| Total Non-current Assets | 6.97B | 7.42B | 7.94B | 8.25B | 8.7B |
| Total Assets | 13.9B | 14.93B | 14.29B | 14.24B | 15.47B |
| Account Payables | 436M | 405M | 411M | 433M | 487M |
| Short-term Debt | 0 | 1.35B | 3M | 1.35B | 53M |
| Tax Payables | 38M | 157M | 110M | 93M | 147M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 11M |
| Other Current Liabilities | 459M | 397M | 484M | 566M | 895M |
| Total Current Liabilities | 1.8B | 3.17B | 1.89B | 3.41B | 2.24B |
| Long-term Debt | 6.59B | 6.55B | 6.56B | 5.22B | 9.24B |
| Deferred Tax Liabilities | 320M | 142M | 146M | 167M | 139M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 17M |
| Other Non-current Liabilities | 496M | 475M | 508M | 494M | 305M |
| Total Non-current Liabilities | 7.56B | 7.36B | 7.41B | 6.06B | 9.9B |
| Total Liabilities | 9.36B | 10.52B | 9.3B | 9.47B | 12.14B |
| Common Stock | 5M | 5M | 5M | 5M | 5M |
| Retained Earnings | 7.19B | 8.67B | 10.3B | 11.97B | 13.74B |
| Accumulated OCI | (764M) | (817M) | (839M) | (940M) | (834M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1M | (2M) | (6M) | 0 | 0 |
| Total Equity | 4.54B | 4.4B | 4.99B | 4.77B | 3.33B |
| Total Debt | 6.74B | 8.09B | 6.76B | 6.74B | 9.49B |
| Net Debt | 3.26B | 4.51B | 4.72B | 4.76B | 7.18B |
Zoetis Inc.
NYSE:ZTS
Intrinsic Alpha fair value
Locked
Current Price
$85.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.